

PRESS RELEASE**STALLERGENES PARTNERS WITH CATALENT AND THE MEDICAL HOUSE FOR
COMMERCIALIZATION OF ADRENALINE AUTOINJECTOR IN EUROPE**

Antony, France; October 7th, 2008 – Stallergenes S.A. today announced that they have entered into an exclusive agreement with Catalent for the promotion and distribution in Europe of adrenaline autoinjector, ADREFLEX[®], co-developed and co-manufactured by Catalent and The Medical House PLC.

ADREFLEX[®] consists of a syringe pre-filled with adrenaline, which will be available for adult and paediatric use (0.3 and 0.15 mg), in an autoinjector device. The Medical House has designed this totally new device to improve the safety and the ease-of-use for patients.

The adrenaline autoinjector is designed for the emergency treatment of anaphylactic shock, mostly due to hymenoptera venom or food allergies, and for use by the patient himself or a relative in the event of an emergency.

Catalent expects to submit the file of ADREFLEX[®] dossier for registration in Europe in 2009. Upon approval, Stallergenes will then promote and distribute the product on an exclusive basis in 13 European countries, including the five main markets (UK, France, Germany, Italy, and Spain).

“This agreement with Catalent and The Medical House fits in perfectly with our product portfolio offered to allergy specialists and with our philosophy regarding state-of-the-art in-licensed complementary products,” said Albert Saporta, Chairman and CEO of Stallergenes. “We expect the European market to double in size in the coming years. Furthermore, this agreement represents a unique opportunity for Stallergenes to set up its own commercial operation in the United Kingdom in the near future. This market accounts for 50% of the adrenaline European market.”

The terms of the agreement are undisclosed.

ABOUT ANAPHYLACTIC SHOCK

Anaphylactic shock is a severe life threatening reaction that can affect all age groups, leading to urticaria and angioedema, bronchoconstriction and hypotension. Mediator release results in smooth muscle contraction, vasodilatation, increased vascular permeability.

Intramuscular adrenaline is a vasoconstrictor, the first line treatment for anaphylactic shock, for patient self administration. Any patient with a severe systemic allergic reaction should be considered for adrenaline autoinjector.

ABOUT STALLERGENES

Stallergenes is a European biopharmaceutical company dedicated to desensitization therapies for the prevention and treatment of allergy-related respiratory diseases, e.g. rhino-conjunctivitis and allergic asthma. A pioneer and leader in sublingual desensitization treatments, Stallergenes devotes 20% in raw data of its turnover to Research and Development and is actively involved in the development of a new therapeutic class: sublingual desensitization tablets.

In 2007, Stallergenes realised sales of € 147 million, mainly achieved in the European markets.

Stallergenes is listed on Euronext Paris (Compartment B) and is part of the sample composing the SBF 120 index.

ISIN code: FR0000065674

Reuters code: GEN.PA

Bloomberg code: GEN.FP



Additional information on Stallergenes is available at: www.stallergenes.com

ABOUT THE MEDICAL HOUSE PLC

The Medical House PLC (TMH) is a group of companies which specialises in the design, development, licensing and supply of innovative medical devices for global pharmaceutical and biotechnology industry clients.

TMH's activities are primarily focused on drug delivery technologies (through Medical House Products Ltd). These activities are supported by in-house design and rapid prototyping capabilities.

Founded in 1998, TMH was admitted to London Stock Exchange's Alternative Investment Market (A.I.M.) in 2000.

For more information, visit www.themedicalhouse.com.

Contacts

Christian Thiry – Financial V.P

Tel.: +33 1 55 59 20 95 – e-mail: investorrelations@stallergenes.fr

Stallergenes press relations

Lise Lemonnier – Communication Manager

Tel.: + 33 1 55 59 20 96 – e-mail: llemonnier@stallergenes.fr

Stallergenes investor and analyst relations

Lucile de Fraguier – Pavie Finance

Tel.: + 33 1 42 15 04 39 – e-mail: contact@pavie-finance.com